Today's episode explores three ideas that caught my attention:
① Disciplined screening can be tested: Yaniv and Alex explain how Mid Atlantic Bio Angels reviewed more than a decade of life science startup applications to ask whether the group’s screening criteria were helping or causing them to miss the winners.
② Life science angel investing has different economics: In therapeutics, medical devices, diagnostics, and digital health, the capital path matters. A company may be promising, but if it needs too much money before reaching an exit, it may be a better fit for venture capital than angel capital.
③ Angel-scale life science exits are about being acquired early: Alex explains why time, capital intensity, clinical risk, and later-stage dilution can make “growing big” less attractive for early angel investors than reaching a strategic acquisition sooner.
Yaniv is a co-founder of Mid Atlantic Bio Angels and a biotech CEO. Alex is an oncology commercialization professional who helped lead a detailed analysis of BioAngels’ screening criteria, applicant outcomes, missed deals, and exit patterns.
During our conversation, Rick shares:
Why BioAngels invests in fewer than 1.5% of companies that apply.
What they learned by analyzing nearly 1,100 life science startup applications.
Why only a small percentage of passed companies reached an exit.
How life science angels think about dilution, time to exit, and capital requirements.
Why one of their first screening questions is: how much money do you need to reach an exit?
Why some companies are better VC opportunities than angel investment opportunities.
What We Cover:
0:00 Introduction
1:36 Why this analysis matters for angel groups
2:16 How BioAngels began looking back at its data
3:25 Alex’s capstone project and the 1,100-company data set
4:44 Why BioAngels invests in fewer than 1.5% of applicants
6:00 Pressure-testing the group’s investment thesis
7:07 How members can still invest outside the group thesis
8:20 BioAngels’ focus on regulated life science products
9:25 Why the group prefers data-heavy science
10:17 What BioAngels looks for in a management team
10:42 Why dilution risk matters for life science angels
12:19 Why clear criteria help founders and investors
13:17 How Alex analyzed 11 years of applications
14:27 What the exit data showed
15:22 Whether BioAngels’ screening criteria worked
16:37 How to analyze passed companies after the fact
19:47 Looking back at the winners BioAngels passed on
22:14 Why every application is a frozen moment in time
24:33 Creating a data analytics committee inside the group
26:58 What the analysis validated and what it refined
29:49 Why angel-scale life science exits are different
30:52 Why time, capital, and dilution change the math
34:29 The “purple unicorn” BioAngels is looking for
37:05 The first screening question BioAngels asks founders
38:54 Final lessons for life science angel investors
40:48 Closing
Check out the entire show library and follow via Apple Podcasts, Spotify, and YouTube.
Connect with Yaniv and Alex
Connect with Andrew
Stuff We Reference
ACA Data Insight: “What Do Outcomes Teach Us About Screening Criteria?”
ACA Data Insight: “IPOs as Outcomes for Life Science Angels: What Changes, and When?”
BioSpace Denatured episode with Yaniv Sneor and Alex Pederson
Know someone who would enjoy this episode? Share it with them!
P.S. Your feedback is important to me. Also, it tells the algorithms to pay more attention, which helps me out a lot. If you enjoyed this episode, hit the “like” button or leave a comment with your thoughts.
All opinions expressed are personal and may not reflect the views of the individual’s organization or of The Diligent Observer. Not investment advice.
